Use of mogamulizumab in cutaneous T-cell lymphomas among people living with HIV: insights from a nationwide French cohort
We report the first nationwide French cohort of people living with HIV treated with mogamulizumab for cutaneous T-cell lymphomas. Mogamulizumab demonstrated sustained efficacy and good tolerability, including in a patient treated continuously for over 3 years, with no opportunistic infections or HIV reactivation. Beyond clinical outcomes, our findings highlight the dual role of CCR4 in HIV persistence and immune regulation, warranting cardiovascular monitoring in this population.
Authors
- Henri Montaudié (ORCID: https://orcid.org/0000-0002-0528-4829)
- Laura Troin
- David Chirio (ORCID: https://orcid.org/0000-0002-7186-2818)
- Perrine Rousset (ORCID: https://orcid.org/0000-0003-4666-5641)
- Nathalie Cardot-Leccia
- Florent Amatore
- Henri Adamski
- Emmanuel Delaporte
- Florence Poizeau
Institutions
- Inserm (FR)
- Aix-Marseille Université (FR)
- Centre Hospitalier Universitaire de Nice (FR)
- Université Rennes 2 (FR)
- Assistance Publique Hôpitaux de Marseille (FR)
- Institut de Recherche en Santé, Environnement et Travail (FR)
- Lymphoma Study Association (FR)
- Université de Rennes (FR)
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2025-12-30
- DOI
- https://doi.org/10.1093/bjd/ljaf534
- Primary Topic
- Cutaneous lymphoproliferative disorders research
- Type
- article
- Field-Weighted Citation Impact
- 0.00